We are live on !
Find out more
Neurocrine Biosciences
NBIX
NBIX
126 hedge funds and large institutions have $778M invested in Neurocrine Biosciences in 2013 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
86.72% more ownership
Funds ownership: 0% → 86.72% (+87%)
45% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $9.9M
Holders
126
Holders Change
+126
Holders Change %
–
% of All Funds
4.1%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.07%
New
–
Increased
–
Reduced
–
Closed
–
Calls
$14.3M
Puts
$9.9M
Net Calls
+$4.43M
Net Calls Change
+$4.43M
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
NBIX Hedge Fund Activity: Q2 2013 in Review
126 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2013, worth a combined $778M.
Fund positioning in NBIX was balanced in Q2 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
- 126 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $778M of Neurocrine Biosciences stock for Q2 2013.
- 0 funds opened new Neurocrine Biosciences positions in Q2 2013 and 0 closed out.
Based on aggregated 13F filings for Q2 2013.